Eintrag weiter verarbeiten
How I treat hepatitis C virus infection in patients with hematologic malignancies
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , |
| In: | Blood, 128, 2016, 11, S. 1449-1457 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Torres, Harrys A. McDonald, George B. Torres, Harrys A. McDonald, George B. |
|---|---|
| author |
Torres, Harrys A. McDonald, George B. |
| spellingShingle |
Torres, Harrys A. McDonald, George B. Blood How I treat hepatitis C virus infection in patients with hematologic malignancies Cell Biology Hematology Immunology Biochemistry |
| author_sort |
torres, harrys a. |
| spelling |
Torres, Harrys A. McDonald, George B. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2016-05-718643 <jats:title>Abstract</jats:title><jats:p>Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-of-care treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages. Similar to the optimal therapy for HCV-infected patients without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly. The choice of regimens with DAAs should be individualized after thorough assessment for potential hematologic toxic effects and drug-drug interactions. This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An up-to-date treatment algorithm is presented.</jats:p> How I treat hepatitis C virus infection in patients with hematologic malignancies Blood |
| doi_str_mv |
10.1182/blood-2016-05-718643 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE2LTA1LTcxODY0Mw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE2LTA1LTcxODY0Mw |
| institution |
DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Hematology, 2016 |
| imprint_str_mv |
American Society of Hematology, 2016 |
| issn |
1528-0020 0006-4971 |
| issn_str_mv |
1528-0020 0006-4971 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
torres2016howitreathepatitiscvirusinfectioninpatientswithhematologicmalignancies |
| publishDateSort |
2016 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_unstemmed |
How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_full |
How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_fullStr |
How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_full_unstemmed |
How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_short |
How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_sort |
how i treat hepatitis c virus infection in patients with hematologic malignancies |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2016-05-718643 |
| publishDate |
2016 |
| physical |
1449-1457 |
| description |
<jats:title>Abstract</jats:title><jats:p>Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-of-care treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages. Similar to the optimal therapy for HCV-infected patients without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly. The choice of regimens with DAAs should be individualized after thorough assessment for potential hematologic toxic effects and drug-drug interactions. This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An up-to-date treatment algorithm is presented.</jats:p> |
| container_issue |
11 |
| container_start_page |
1449 |
| container_title |
Blood |
| container_volume |
128 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346383975448582 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:38:30.24Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=How+I+treat+hepatitis+C+virus+infection+in+patients+with+hematologic+malignancies&rft.date=2016-09-15&genre=article&issn=1528-0020&volume=128&issue=11&spage=1449&epage=1457&pages=1449-1457&jtitle=Blood&atitle=How+I+treat+hepatitis+C+virus+infection+in+patients+with+hematologic+malignancies&aulast=McDonald&aufirst=George+B.&rft_id=info%3Adoi%2F10.1182%2Fblood-2016-05-718643&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346383975448582 |
| author | Torres, Harrys A., McDonald, George B. |
| author_facet | Torres, Harrys A., McDonald, George B., Torres, Harrys A., McDonald, George B. |
| author_sort | torres, harrys a. |
| container_issue | 11 |
| container_start_page | 1449 |
| container_title | Blood |
| container_volume | 128 |
| description | <jats:title>Abstract</jats:title><jats:p>Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-of-care treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages. Similar to the optimal therapy for HCV-infected patients without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly. The choice of regimens with DAAs should be individualized after thorough assessment for potential hematologic toxic effects and drug-drug interactions. This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An up-to-date treatment algorithm is presented.</jats:p> |
| doi_str_mv | 10.1182/blood-2016-05-718643 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE2LTA1LTcxODY0Mw |
| imprint | American Society of Hematology, 2016 |
| imprint_str_mv | American Society of Hematology, 2016 |
| institution | DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 1528-0020, 0006-4971 |
| issn_str_mv | 1528-0020, 0006-4971 |
| language | English |
| last_indexed | 2024-03-01T17:38:30.24Z |
| match_str | torres2016howitreathepatitiscvirusinfectioninpatientswithhematologicmalignancies |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 1449-1457 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Torres, Harrys A. McDonald, George B. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2016-05-718643 <jats:title>Abstract</jats:title><jats:p>Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-of-care treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages. Similar to the optimal therapy for HCV-infected patients without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly. The choice of regimens with DAAs should be individualized after thorough assessment for potential hematologic toxic effects and drug-drug interactions. This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An up-to-date treatment algorithm is presented.</jats:p> How I treat hepatitis C virus infection in patients with hematologic malignancies Blood |
| spellingShingle | Torres, Harrys A., McDonald, George B., Blood, How I treat hepatitis C virus infection in patients with hematologic malignancies, Cell Biology, Hematology, Immunology, Biochemistry |
| title | How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_full | How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_fullStr | How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_full_unstemmed | How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_short | How I treat hepatitis C virus infection in patients with hematologic malignancies |
| title_sort | how i treat hepatitis c virus infection in patients with hematologic malignancies |
| title_unstemmed | How I treat hepatitis C virus infection in patients with hematologic malignancies |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2016-05-718643 |